hcai

hCAIX-IN-5 was a selective hCAIX inhibitor, inhibiting hCAI, hCAII, hCAIV, and hCAIX with Ki values of >10000, >10000, 130.7, and 829.1 nM, respectively.

Methazolamide (CL 8490) is a carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.

Histone acetyltransferase p300 Inhibitor 4c is a 2-aminothiazole derivative. Histone acetyltransferase p300 Inhibitor 4c inhibited hCA I, hCA II, AChE and BChE with Ki values of 0.008 ± 0.001, 0.124 ± 0.017, 0.129 ± 0.030 and 0.083 ± 0.041 µM. 0.017, 0.129 ± 0.030 and 0.083 ± 0.041 μM.

hCAI/II/IV-IN-28(WAY-638358) is a potent carbonic anhydrase inhibitor with potential anticonvulsant activity.

hCAI/II-IN-10 (Compound 5d) is an inhibitor of human carbonic anhydrase I and II (hCA I and hCA II), with IC50 values of 4.32 nM and 3.89 nM, respectively.

hCAI/II/XII-IN-1 (compound 7) is an inhibitor of human carbonic anhydrases hCAI, hCAII, and hCAXII, with Ki values of 78.5 nM, 9.1 nM, 605 nM, 7.7 nM, and 3.7 nM.

hCAI/II-IN-11 (compound 2c) is a carbonic anhydrase inhibitor with IC50 values of 12.56 μM and 13.02 μM for hCAI and hCA II, respectively. In addition, hCAI/II-IN-11 exhibits antioxidant and antibacterial properties.

hCAI/II-IN-8 (Compound 8) is a hydrazone derivative originating from 4-hydroxybenzaldehyde. It primarily inhibits human carbonic anhydrase isoenzymes I (hCA I) and II (hCA II) with IC50 values of 21.35 ± 0.39 nM for hCA I and 7.12 ± 0.12 nM for hCA II. It also exhibits inhibitory effects on AChE and BChE, with IC50 values of 46.27 ± 0.75 nM and 43.38 ± 0.83 nM, respectively.

hCAI/II-IN-2 (compound 2b) is a highly effective dual inhibitor of human carbonic anhydrase I and II (hCA I/II), with Ki values of 40.97 nM for hCA I, 15.15 nM for hCA II, and 61.88 nM for hCA IX. With its anti-hypoxic properties, hCAI/II-IN-2 demonstrates activity against acute mountain sickness (AMS) and exhibits low cellular activity [1].

hCAI/II-IN-4 (compound 6d) is a potent inhibitor of both hCA I and hCA II enzymes, with Ki values of 16.95 nM and 15.22 nM, respectively. It also inhibits hCA IX with a Ki value of 27.04 nM, exhibits anti-hypoxia properties, and maintains low toxicity. This compound is suitable for investigating acute mountain sickness (AMS) in research studies [1].

hCAI/II-IN-6 is a selective and orally active inhibitor of human carbonic anhydrase (CA). hCAI/II-IN-6 inhibited hCA I, hCA II, hCA VII, and hCA XII with Ki values of 220, 4.9, 6.5, and ＞50,000 nM. hCAI/II-IN-6 showed anticonvulsant activity in vivo. hCAI/II-IN-6 can be used to study epilepsy. hCAI/II-IN-6 showed anticonvulsant activity in vivo. hCAI/II-IN-6 can be used to study epilepsy.

hCAI/II-IN-3 (compound 5b) is a highly effective dual inhibitor of hCA I/II enzymes, exhibiting Ki values of 51.25, 13.15, and 42.18 nM for hCA I, hCA II, and hCA Ⅸ, respectively. It demonstrates anti-hypoxic properties against acute mountain sickness (AMS) and exhibits low cellular activity [1].

hCAI/II-IN-1 (Compound 3h) is a human carbonic anhydrase I and II (hCA I/II) inhibitor, with an IC50 value of 0.047 μM for hCA I and 0.024 μM for hCA II.

hCAI/II-IN-5 is a potent inhibitor of hCA I and hCA II (human carbonic anhydrase isozymes I and II), with IC50 values of 37.88 and 45.23 nM, respectively. hCAI/II-IN-5 also inhibits α-Glycosidase (IC50: 48.98 nM) and AChE (IC50: 420.14 nM). nM). hCAI/II-IN-5 can be used in the study of diabetes, heart failure, Alzheimer's disease, ulcers, epilepsy and many other diseases.

hCAI/II-IN-7 (compound 1F) is an effective carbonic anhydrase (CA) inhibitor with Ki values of 23 nM, 44 nM, and 21 μM for hCA-I, hCA-II, and bCA respectively.

Compound CDy9 is a highly selective inhibitor of carbonic anhydrase (CA) with an IC50 value of 0.18 μM for hCA II.

hCAII-IN-9 is a potent carbonic anhydrase inhibitor with IC50 values of 1.18 μM for hCA II, 0.17 μM for hCA IX, and 2.99 μM for hCA XII. It is not blood-brain barrier permeable.

hCAII-IN-10 (compound 11d) is an inhibitor of hCAII with IC50 values of 14 nM for hCAII and 29.2 μM for hCAI. It demonstrates inhibitory effects on HT-29 cells with an IC50 of 74 μM and is effective in reducing intraocular pressure in a rabbit model of glaucoma.

hCAIX-IN-7 (compound 6c) is a potent and selective inhibitor of the tumor-associated isoform hCAIX, with inhibition constants (KIs) of >10000 nM for hCAI and hCAII, 43.0 nM for hCAIV, and 410.6 nM for hCAIX [1].

hCAIX/XII-IN-2 (compound 6a) is a potent and selective inhibitor of hCAIX and hCAXII, with Ki values of >10000 nM for hCAI and hCAII, and 30.0 nM and 3.6 nM for hCAIX and hCAXII respectively [1].

hCAIX/XII-IN-3 (compound 6q) is a potent, selective inhibitor of hCAIX and hCAXII, with K i values of >10000 nM for hCAI and hCAII, and 66.2 nM and 4.4 nM for hCAIX and hCAXII, respectively.

hCAIX-IN-19 is a sulfonamide inhibitor with an inhibition constant (KI) of 6.2 nM for hCAIX, exhibiting significant selectivity towards hCAIX over hCAI (hCA I/hCAIX = 117).

hCAIX-IN-18 (compound 30), a potent inhibitor of the carbonic anhydrase enzyme family (CA), exhibits K i values of 3.5 nM for hCAI, 9.4 nM for hCAII, 43.0 nM for hCAIX, and 8.2 nM for hCAXII. This compound is applicable in cancer research [1].

hCAIX/XII-IN-13 functions as an inhibitor targeting specific human carbonic anhydrases (hCA) IX and XII, crucial in tumor-related processes. Demonstrating efficacy, this compound offers inhibitory K i values of 0.08 µM for IX and 0.06 µM for XII. Additionally, under hypoxic conditions, hCAIX/XII-IN-13 enhances the effectiveness of Doxorubicin on MCF-7 cells by promoting G2/M phase cell cycle arrest and increasing apoptosis.